Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
Description
Waning immunity and emerging variants necessitate continued vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Improvements in vaccine safety, tolerability, and ease of manufacturing would benefit these efforts. Here
